Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab

Clinical Rheumatology

Volumn 33, Issue 6, 2014, Pages 799-805

  Heusele, Marion ^a   Clerson, Pierre ^b   Guery, Benoit ^a   Lambert, Marc ^a   Launay, David ^a   Lefevre, Guillaume ^a   Morell Dubois, Sandrine ^a   Maillard, Hélène ^a   Le Gouellec, Noémie ^a   Hatron, Pierre Yves ^a   Hachulla, Eric ^a  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b Orgamétrie Biostatistiques Roubaix   (France)

Author keywords

Infectious risk; Rituximab; Systemic autoimmune diseases; Systemic lupus erythematosus; Vasculitis

Indexed keywords

CREATININE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; PNEUMOCOCCUS VACCINE; PREDNISONE; RITUXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANCA ASSOCIATED VASCULITIS; ANTIPHOSPHOLIPID SYNDROME; ARTHRALGIA; ARTICLE; ASTHENIA; AUTOIMMUNE DISEASE; AUTOIMMUNE HEMOLYTIC ANEMIA; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BRONCHITIS; CASE CONTROL STUDY; CD4 LYMPHOCYTE COUNT; CELLULITIS; CLINICAL ARTICLE; CREATININE CLEARANCE; DIABETES MELLITUS; DIARRHEA; DRUG ERUPTION; DRUG INDUCED HEADACHE; FEBRILE NEUTROPENIA; FEMALE; FLU LIKE SYNDROME; HUMAN; HYPERTHERMIA; IDIOPATHIC MIXED CRYOGLOBULINAEMIA VASCULITIS; IDIOPATHIC THROMBOCYTOPENIC PURPURA; KIDNEY FAILURE; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; PRIORITY JOURNAL; RISK FACTOR; SERUM SICKNESS; SINUSITIS; STREPTOCOCCUS PNEUMONIAE; SYSTEMIC AUTOIMMUNE DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; YOUNG ADULT; BLOOD; COMPLICATION; DOSE RESPONSE; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICROBIOLOGY; TREATMENT OUTCOME; VASCULITIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; BACTERIAL INFECTIONS; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULIN G; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDNISONE; RISK FACTORS; TREATMENT OUTCOME; VASCULITIS;

EID: 84903817330     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-014-2509-2     Document Type: Article

References (21)

1. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soto MJ, Biogeas Study Group (2008) A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 87:345-364
2. Stashenko P, Nadler LM, Hardy R, Schlossman SF (1980) Characterization of a human B lymphocyte-specific antigen. J Immunol 125:1678-1685 (Pubitemid 10018582)
3. Keystone E, Fleischmann R, Emery P et al (2007) Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 56:3896-3908 (Pubitemid 350262316)
4. St Clair EW (2010) Good and bad memories following rituximab therapy. Arthritis Rheum 62:1-5
5. Muhammad K, Roll P, Einsele H, Dörner T, Tony HP (2009) Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment. Arthritis Rheum 60:2284-2293
6. Rovin BH, Furie R, Latinis K et al (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64:1215-1226
7. Merrill JT, Neuwelt CM, Wallace DJ et al (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62:222-233
8. Stone JH, Merkel PA, Spiera R et al (2010) Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 363:221-232
9. Jones RB, Tervaert JW, Hauser T et al (2010) Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363:211-220
10. Diaz-Lagares C, Perez-Alvarez R, Garcia-Hernandez FJ et al (2011) Rates of, and risk factors for, severe infections in patients with systemic autoimmune diseases receiving biological agents off-label. Arthritis Res Ther 13:R112
11. Terrier B, Amoura Z, Ravaud P et al (2010) Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 62:2458-2466
12. Tony HP, Burmester G, Schulze-Koops H et al (2011) Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 13:R75
13. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1996) CDC definitions for nosocomial infections. In: Olmsted RN (ed) APIC infection control and applied epidemiology: principles and practice. Mosby, St. Louis, pp A-1-A-20
14. Kollef MH, Napolitano LM, Solomkin JS et al (2008) Health care-associated infection (HAI): a critical appraisal of the emerging threat-proceedings of the HAI summit. Clin Infect Dis 47(Suppl 2):S55-S99
15. Lujan M, Gallego M, Rello J (2009) Healthcare-associated infections. A useful concept? Curr Opin Crit Care 15:419-424
16. Fleischmann RM (2009) Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases: focus on rituximab. Semin Arthritis Rheum 38:265-280
17. Gottenberg JE, Ravaud P, Bardin T et al (2010) Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 62:2625-2632
18. van Vollenhoven RF, Emery P, Bingham CO 3rd et al (2010) Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37:558-567
19. PhamT, Fautrel B, Gottenberg JE et al (2008) Rituximab (MabThera) therapy and safety management. Clinical tool guide. Joint Bone Spine 75(Suppl 1):S1-S99
20. Stuck AE, Minder CE, Frey FJ (1989) Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11:954-963
21. Pepper R, GriffithM, Kirwan C et al (2009) Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. Nephrol Dial Transplant 24:3717-3723